Kirk Tanner

Company: National Brain Tumor Society

Job title: Senior Vice President - Brain Tumor Investment Fund

Seminars:

Panel Discussion: What’s Next for DDR Therapeutics? Evaluating Next-Gen PARP Inhibitors, Novel Targets, & the Future of Clinical Validation 4:15 pm

How are biopharma validating novel DDR targets, and what role will next-gen PARP inhibitors play in the evolving landscape of DDR therapeutics? What preclinical frameworks are currently in use for DDR inhibitors, and how can they be enhanced to better predict clinical success and viability? As we look to the future, could expanding data access—such…Read more

day: Day Two

Fireside Chat: Targeting the DDR in Brain Tumors: Trials, Tribulations, & Future Directions 5:00 pm

What evidence supports DDR as a therapeutic target in brain tumors, and are there specific subtypes where it shows more promise? Why have DDR-targeting therapies, including PARP inhibitors, faced limited success in brain tumor treatments despite their efficacy in other cancers? What strategies could overcome current barriers in DDR targeted therapy for brain tumors and…Read more

day: Day One